Harnessing Chaperones to Generate Small-Molecule Inhibitors of Amyloid ß Aggregation

Protein aggregation is involved in the pathogenesis of neurodegenerative diseases and hence is considered an attractive target for therapeutic intervention. However, protein-protein interactions are exceedingly difficult to inhibit. Small molecules lack sufficient steric bulk to prevent interactions between large peptide surfaces. To yield potent inhibitors of β-amyloid (Aβ) aggregation, we synthesized small molecules that increase their steric bulk by binding to chaperones but also have a moiety available for interaction with Aβ. This strategy yields potent inhibitors of Aβ aggregation and could lead to therapeutics for Alzheimer's disease and other forms of neurodegeneration.

[1]  Andrzej Galat,et al.  Molecular cloning and overexpression of the human FK506-binding protein FKBP , 1990, Nature.

[2]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[3]  D. Westaway,et al.  Transgenic mouse models of Alzheimer's disease. , 2000, Biochimica et biophysica acta.

[4]  J. Ashby References and Notes , 1999 .

[5]  K. Stankunas,et al.  Conditional protein alleles using knockin mice and a chemical inducer of dimerization. , 2003, Molecular cell.

[6]  Peter T. Lansbury,et al.  Carbon Nanotube Tips: High-Resolution Probes for Imaging Biological Systems , 1998 .

[7]  K. Haldar,et al.  A bifunctional molecule that displays context-dependent cellular activity. , 2003, Journal of the American Chemical Society.

[8]  S. Schreiber,et al.  Controlling signal transduction with synthetic ligands. , 1993, Science.

[9]  M. Findeis,et al.  Approaches to discovery and characterization of inhibitors of amyloid beta-peptide polymerization. , 2000, Biochimica et biophysica acta.

[10]  T. Clackson,et al.  Regulation of endogenous gene expression with a small-molecule dimerizer , 2002, Nature Biotechnology.

[11]  L. Kiessling,et al.  A Strategy for Designing Inhibitors of β-Amyloid Toxicity* , 1996, The Journal of Biological Chemistry.

[12]  V. Lee,et al.  Amyloid binding ligands as Alzheimer’s disease therapies , 2002, Neurobiology of Aging.

[13]  M. Citron,et al.  Emerging Alzheimer’s disease therapies: inhibition of β-secretase , 2002, Neurobiology of Aging.

[14]  D. Selkoe,et al.  Deciphering the genetic basis of Alzheimer's disease. , 2002, Annual review of genomics and human genetics.

[15]  W. Klein Aβ toxicity in Alzheimer’s disease: globular oligomers (ADDLs) as new vaccine and drug targets , 2002, Neurochemistry International.

[16]  P. Lansbury,et al.  Amyloid diseases: abnormal protein aggregation in neurodegeneration. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[18]  H. Levine Quantification of beta-sheet amyloid fibril structures with thioflavin T. , 1999, Methods in enzymology.

[19]  Peter T. Lansbury,et al.  Assembly of Aβ Amyloid Protofibrils: An in Vitro Model for a Possible Early Event in Alzheimer's Disease† , 1999 .

[20]  P. Lewi,et al.  Protein–protein interactions: mechanisms and modification by drugs , 2002, Journal of molecular recognition : JMR.

[21]  A. Mccarthy Development , 1996, Current Opinion in Neurobiology.

[22]  W. Delano,et al.  Convergent solutions to binding at a protein-protein interface. , 2000, Science.

[23]  宁北芳,et al.  疟原虫var基因转换速率变化导致抗原变异[英]/Paul H, Robert P, Christodoulou Z, et al//Proc Natl Acad Sci U S A , 2005 .

[24]  Andrzej Galat,et al.  Peptidylprolyl cis/trans isomerases (immunophilins): biological diversity--targets--functions. , 2003, Current topics in medicinal chemistry.

[25]  G. Crabtree,et al.  Affinity modulation of small-molecule ligands by borrowing endogenous protein surfaces. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Fred E. Cohen,et al.  Therapeutic approaches to protein-misfolding diseases , 2003, Nature.

[27]  James C. Sacchettini,et al.  Therapeutic strategies for human amyloid diseases , 2002, Nature Reviews Drug Discovery.

[28]  F. Young Biochemistry , 1955, The Indian Medical Gazette.

[29]  Jon Clardy,et al.  DESIGN, SYNTHESIS, AND KINETIC EVALUATION OF HIGH-AFFINITY FKBP LIGANDS AND THE X-RAY CRYSTAL-STRUCTURES OF THEIR COMPLEXES WITH FKBP12. , 1994 .

[30]  M. Michaelis Drugs Targeting Alzheimer's Disease: Some Things Old and Some Things New , 2003, Journal of Pharmacology and Experimental Therapeutics.